ViVac Pharma receives NIS 100,000 award for its work on programmable RNA immunotherapies targeting solid tumors. | Read More in JPost.com – Business & Innovation | The Jerusalem Post
Recent Posts
The Jerusalem Post
What does Tom Barrack’s warning on Saudi Arabia reveal about US Middle East policy? – analysis
October 20, 2026Are newsrooms burying Iranian efforts to influence midterms? – opinion
October 20, 2026- October 20, 2026
Iran prolongs talks in stalemate to punish Trump ahead of US midterms, officials say
October 20, 2026
YnetNews
A generation in economic crisis: Europe’s young people take to the streets as protests spread
October 20, 2026IDF will ‘allow democratic elections to take place without external interference,’ says IDF chief
October 20, 2026‘Bombing will resume sooner or later’: Iran prepares for US-Israeli attacks amid Hormuz tensions
October 20, 2026Report: UK to deploy fighter jets to defend Saudi Arabia from Houthi attacks
October 20, 2026
Arutz Sheva
Was Israel warned before the October 7 attacks?October 20, 2026
A little girl, a family’s world, and a fight no child should ever faceOctober 20, 2026
Pakistan steps in as US-Iran tensions threaten renewed conflictOctober 20, 2026
Katz threatens to expand control in Lebanon if Hezbollah attacksOctober 20, 2026
JTA
Hebrew University start-up wins Asper Prize for approach to cancer treatment
October 20, 2026- Hebrew University start-up wins Asper Prize for approach to cancer treatmentOctober 20, 2026
- Hebrew University start-up wins Asper Prize for approach to cancer treatmentOctober 20, 2026
- Hebrew University start-up wins Asper Prize for approach to cancer treatmentOctober 20, 2026
Tesla approaches Q3 earnings amid Roadster buzz and expansion
October 20, 2026